NeuroPace to Present RNS System at Cantor and Wells Fargo Healthcare Conferences
核心洞察
NeuroPace, Inc. (搜索) (Nasdaq: NPCE) will participate in the 2026 Cantor Global Healthcare Conference with a fireside chat on September 9 at 10:55am EDT.
The company will also join the Wells Fargo 21st Annual Healthcare Conference for a fireside chat on September 8 at 8:00am EDT.
NeuroPace's RNS System (搜索) is the first and only commercially available brain-responsive platform delivering personalized, real-time treatment at the seizure source.
NeuroPace, Inc. (搜索) (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy (搜索), announced that its management team will participate in two upcoming investor healthcare conferences in September 2026.
The company will take part in the Wells Fargo 21st Annual Healthcare Conference, where management will host a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, along with one-on-one meetings with investors. The following day, NeuroPace management will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9 at 10:55am EDT, and will also host one-on-one investor meetings during the conference.
Both fireside chats will be accessible via live webcast, with replays available on the Events section of NeuroPace's Investor website.
The RNS System Platform
Based in Mountain View, Calif., NeuroPace is focused on reducing or eliminating the occurrence of debilitating seizures in people living with epilepsy (搜索). Its novel and differentiated RNS System (搜索) is described by the company as the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.
According to the company, this platform can drive a better standard of care for patients living with drug-resistant epilepsy (搜索). Beyond epilepsy (搜索), NeuroPace states that the RNS System (搜索) has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.